Oruka Therapeutics (0H79) Share Forecast & Price Target
0H79 Analyst Ratings
0H79 Stock 12 Month Forecast
Average Price Target
$151.90▲(0.00% Upside)Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | $160 | buy | ― | Reiterated | 10/27/26 | ||
| Mitchell Kapoor | H.C. Wainwright | $120 | buy | ― | Reiterated | 10/27/26 | ||
 Unknown AnalystNot Ranked | Wedbush | $165 | buy | ― | Reiterated | 10/27/26 | ||
| David Risinger | Leerink Partners | ― | buy | ― | Reiterated | 10/27/26 | ||
| Kaveri Pohlman | Clear Street | $131→$105 | buy | ― | Reiterated | 10/26/26 | ||
| Julian Harrison | BTIG | $151 | buy | ― | Reiterated | 10/26/26 | ||
| Yasmeen Rahimi | Piper Sandler | $180 | buy | ― | Reiterated | 10/07/26 | ||
| Sam Slutsky | LifeSci Capital | $175 | buy | ― | Reiterated | 09/23/26 | ||
| Michael Yee | UBS | $130 | buy | ― | Reiterated | 09/01/26 | ||
| Tyler Van Buren | TD Cowen | ― | buy | ― | Reiterated | 08/26/26 | ||
| Roger Song | Jefferies | $133 | buy | ― | Reiterated | 08/11/26 | ||
| Yatin Suneja | Guggenheim | $200 | buy | ― | Reiterated | 08/10/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | $150 | buy | ― | Reiterated | 06/29/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | 10/27/26 | $160 | buy | ― | Reiterated | Barclays | ||
| Mitchell Kapoor | 10/27/26 | $120 | buy | ― | Reiterated | H.C. Wainwright | ||
| Unknown AnalystNot Ranked | 10/27/26 | $165 | buy | ― | Reiterated | Wedbush | ||
| David Risinger | 10/27/26 | ― | buy | ― | Reiterated | Leerink Partners | ||
| Kaveri Pohlman | 10/26/26 | $131→$105 | buy | ― | Reiterated | Clear Street | ||
| Julian Harrison | 10/26/26 | $151 | buy | ― | Reiterated | BTIG | ||
| Yasmeen Rahimi | 10/07/26 | $180 | buy | ― | Reiterated | Piper Sandler | ||
| Sam Slutsky | 09/23/26 | $175 | buy | ― | Reiterated | LifeSci Capital | ||
| Michael Yee | 09/01/26 | $130 | buy | ― | Reiterated | UBS | ||
| Tyler Van Buren | 08/26/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Roger Song | 08/11/26 | $133 | buy | ― | Reiterated | Jefferies | ||
| Yatin Suneja | 08/10/26 | $200 | buy | ― | Reiterated | Guggenheim | ||
| Alex Thompson CFA | 06/29/26 | $150 | buy | ― | Reiterated | Stifel Nicolaus |
Best Analysts Covering Oruka Therapeutics
Copying Julian Harrison's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +49.42% per trade.
Copying David Risinger's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +257.45% per trade.
Copying David Risinger's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +356.26% per trade.
0H79 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 24 | 14 | 13 | 13 | 17 |
| Buy | 9 | 4 | 7 | 9 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 33 | 18 | 20 | 22 | 28 |
In the current month, 0H79 has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0H79 average Analyst price target in the past 3 months is 151.90.
0H79 Financial Forecast
0H79 Earnings Forecast
Next quarter’s earnings estimate for 0H79 is -$0.60 with a range of -$0.79 to -$0.32. The previous quarter’s EPS was -$0.55. 0H79 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0H79 has Performed in-line its overall industry.
0H79 Sales Forecast
Next quarter’s sales forecast for 0H79 is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. 0H79 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0H79 has Performed in-line its overall industry.